alpha-glucosidase inhibitor

DRUG3 trials

Sponsors

Tanabe Pharma Corporation, GlaxoSmithKline, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Conditions

Diabetes MellitusType 2 Diabetes MellitusType2diabetes

Phase 3

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

CompletedNCT01301833

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2011-02-28End: 2012-09-30Updated: 2026-01-02

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

CompletedNCT01777282

GlaxoSmithKlineDiabetes Mellitus

Start: 2013-02-23End: 2015-01-27Updated: 2017-05-03

Phase 4

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruitingNCT06449235

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersType2diabetes

Start: 2024-09-30End: 2025-06-30Target: 938Updated: 2024-07-16

Related Papers

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.

2016-12-216 citations